Showing results (1-10 of 127) with videos related to
Sort By:
Pageof 13
The Veterinary Clinics of North America. Small Animal Practice|July 16, 2011
Alterations of drug metabolism in critically ill animalsEileen S Hackett, Daniel L GustafsonCancer Chemotherapy and Pharmacology|April 22, 2010
Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude miceCathrine L Denton, Daniel L GustafsonJournal of Pharmacokinetics and Pharmacodynamics|April 26, 2013
Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in miceSusan F Hudachek, Daniel L GustafsonJournal of Pharmaceutical Sciences|August 31, 2010
Customized in silico population mimics actual population in docetaxel population pharmacokinetic analysisSusan F Hudachek, Daniel L GustafsonAnti-Cancer Drugs|August 10, 2013
Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of miceSusan F Hudachek, Daniel L GustafsonVeterinary and Comparative Oncology|September 6, 2019
Drug dose and drug choice: Optimizing medical therapy for veterinary cancerDouglas H Thamm, Daniel L GustafsonChemico-Biological Interactions|February 8, 2011
Optimizing preclinical study design in oncology researchLuke A Wittenburg, Daniel L GustafsonJournal of Pharmacokinetics and Pharmacodynamics|January 15, 2013
Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humansSusan F Hudachek, Daniel L GustafsonThe Journal of Pharmacology and Experimental Therapeutics|September 10, 2021
Pharmacokinetic and Pharmacodynamic Assessment of Hydroxychloroquine in Breast CancerKristen M Van Eaton, Daniel L GustafsonJournal of Veterinary Pharmacology and Therapeutics|September 7, 2019
The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown originAslynn Jones, Stephanie McGrath, Daniel L GustafsonPageof 13